Kratom extract is a concentrated preparation of alkaloids from the leaves of Mitragyna speciosa, a tropical tree native to Southeast Asia. Unlike raw kratom powder, which is simply dried and ground leaf, an extract uses solvents or other processing to pull out and concentrate the pharmacologically active compounds, resulting in a product that can be many times more potent per gram. The trouble is that “extract” on a kratom label can mean almost anything: the concentration method, the alkaloid profile, and the actual potency vary enormously from product to product, and labels frequently do not match what is inside the package.
What Makes an Extract Different From Leaf Powder
Raw kratom leaf contains dozens of alkaloids, but four dominate: mitragynine, paynantheine, speciociliatine, and speciogynine. In a broad analysis of kratom leaf products and extracts, mitragynine content ranged from 0.7% to nearly 39% by weight, while secondary alkaloids like paynantheine ranged from 0.3% to about 13%.1PubMed Central. Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry That enormous spread is itself telling: even within a single product category, what you are getting can differ by a factor of fifty.
When manufacturers produce an extract, the solvent they choose changes the result. Laboratory testing using methanol, ethanol, and ethyl acetate found that mitragynine content in the resulting extracts ranged from roughly 2% to 7%, depending on the solvent’s polarity.2PubMed Central. Accelerated Solvent Extractions (ASE) of Mitragyna speciosa Korth. (Kratom) Leaves: Evaluation of Its Cytotoxicity and Antinociceptive Activity Commercial manufacturers often go further, using repeated extractions or enrichment steps to boost specific alkaloids. The result is a product that packs far more active compound into a smaller volume, which is precisely why extracts carry disproportionate risk.
Whole-leaf kratom products, by contrast, tend to be more compositionally similar to one another. A nationwide study analyzing 341 kratom samples found that most whole-leaf products shared a consistent alkaloid fingerprint matching what you would expect from raw Mitragyna speciosa leaf material, with a median mitragynine intake per use of about 25 mg.3PubMed Central. Chemical Analysis and Alkaloid Intake for Kratom Products Available in the United States Extracts throw that consistency out the window.
How Kratom Alkaloids Work in the Body
Kratom’s effects are driven primarily by mitragynine and a minor but much more potent alkaloid called 7-hydroxymitragynine (often abbreviated 7-HMG). Both interact with the mu-opioid receptor, the same target that morphine and fentanyl act on, but they do so in a more selective way. Research has shown that mitragynine and 7-HMG are “G-protein-biased” agonists, meaning they activate one signaling pathway at the receptor while largely skipping another pathway linked to respiratory depression and other dangerous opioid side effects.4PubMed Central. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators This biased signaling is part of why kratom has attracted interest from pain researchers and why some users report opioid-like pain relief with what they perceive as a wider safety margin.
The picture is more complicated than “a safer opioid,” though. In lab assays using human receptors, mitragynine has relatively low binding affinity at the mu-opioid receptor and actually behaves as an antagonist (it blocks the receptor rather than activating it). Meanwhile, 7-HMG has about nine times higher affinity and acts as a partial agonist, producing meaningful opioid-like activation.5PubMed Central. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for μ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats In living animals, the pharmacology shifts because the body metabolizes mitragynine into 7-HMG and other active compounds, which may explain why whole-plant kratom feels different from either alkaloid in isolation.
Beyond opioid receptors, kratom alkaloids also interact with adrenergic, serotonin, and dopamine receptors, which collectively account for the stimulant-like energy at low doses, the mood lift, and the sedation at higher doses that users report.6PubMed Central. Kratom Alkaloids: A Blueprint? Two of the secondary alkaloids, paynantheine and speciogynine, show strong affinity for serotonin 5-HT1A receptors and produce pain-relieving effects through a mechanism that does not involve opioid receptors at all. Their metabolites appear to be the ones actually driving serotonin receptor activation, and these metabolites did not activate a serotonin receptor subtype associated with heart valve damage.7PubMed Central. Activity of Mitragyna speciosa (“Kratom”) Alkaloids at Serotonin Receptors This matters because an extract that strips out or disproportionately concentrates certain alkaloids over others will produce a different pharmacological experience than the whole leaf.
Why Potency Is So Hard to Pin Down
If you buy a kratom extract labeled “50x” or “100x,” that multiplier has no standardized meaning. It could refer to the volume of leaf used to produce the extract, the supposed mitragynine concentration relative to leaf, or essentially nothing at all. Laboratory analyses of commercial kratom products show that mitragynine levels in commercial products span from about 14 mg/g up to 270 mg/g, a nearly twenty-fold range.8PubMed Central. Kratom (Mitragyna speciosa) Validation: Quantitative Analysis of Indole and Oxindole Alkaloids Reveals Chemotypes of Plants and Products Two products sitting side by side on a shelf, both labeled as extracts, could contain wildly different amounts of every active compound.
The more dangerous variable is often 7-HMG, the alkaloid with the strongest opioid activity. In whole-leaf kratom, 7-HMG is a minor constituent, typically present at very low levels. But some extract manufacturers deliberately concentrate it or add it back as a semi-synthetic ingredient. An analysis of products marketed as kratom found that 7-HMG was the most abundant alkaloid in certain products, with concentrations ranging from 22 to 75 mg per gram, often 5% to 28% higher than what the labels claimed.9Journal of AOAC INTERNATIONAL. Elevated 7-Hydroxymitragynine Levels Found in Products Misbranded as Kratom That is a completely different substance profile than traditional kratom leaf, where mitragynine dominates and 7-HMG is a trace ingredient.
The Labeling Problem
Mislabeling is not an occasional quality-control lapse; it is the norm in large swaths of the kratom extract market. A study examining semi-synthetic kratom-derived products (tablets, films, and liquid shots) found substantial variability in what they contained versus what their labels said. Products frequently contained unreported alkaloids or lacked ones that were listed. Many included pharmacologically potent compounds like 7-HMG and 3-dehydromitragynine regardless of whether those appeared on the label.10PubMed. Mislabeling and Status of Semisynthetic Kratom-Derived Products in the US Market
The practical consequence is that even a careful consumer who reads labels and tries to dose conservatively has no reliable way to know what they are taking. A product claiming a specific milligram amount of mitragynine per serving might also contain a hefty dose of 7-HMG that is nowhere on the label. This is especially concerning because 7-HMG’s opioid receptor potency is many times greater than mitragynine’s, meaning even a modest unlisted amount can substantially change the product’s effects and risks.
The Rise of Semi-Synthetic Products
A newer and rapidly expanding segment of the market consists of semi-synthetic kratom products, particularly those built around concentrated 7-HMG or a compound called mitragynine pseudoindoxyl (MP). A market survey identified over 300 such products. Most were 7-HMG-only formulations sold as chewable tablets, liquid shots, or gummies. About 92% of these products were marketed as “kratom,” even though they are chemically quite distinct from whole-leaf kratom. Over a third made claims about pain or anxiety relief, and some had names clearly alluding to prescription opioids.11PubMed Central. De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing These products represent a meaningful escalation in potency and risk compared to traditional kratom leaf or even standard extracts, yet they sit on the same shelves and websites.
Drug Interactions
One of the less-discussed risks of kratom, and particularly of extracts, is the way its alkaloids interfere with the liver enzymes that metabolize other drugs. Mitragynine is a strong inhibitor of the enzyme CYP2D6, which the body uses to process a long list of common medications including certain antidepressants, beta-blockers, and codeine. Other kratom alkaloids also moderately inhibit CYP2C19 and CYP3A enzymes.12PubMed Central. Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids
A clinical study in healthy adults found that even a low dose of kratom tea (2 grams of leaf material) produced a modest but real increase in blood levels of a drug metabolized by CYP3A, without changing levels of a CYP2D6-metabolized probe drug at that dose. The researchers concluded that the inhibition primarily affected an intestinal form of the CYP3A enzyme and flagged the potential for serious interactions when kratom is taken alongside drugs that rely heavily on CYP3A for clearance.13PubMed Central. Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom That study used a low dose of whole leaf. With concentrated extracts delivering many times more alkaloid, the inhibitory effect on these enzymes could be proportionally greater, and the risk of dangerously elevated blood levels of co-administered drugs increases accordingly.
Lab testing of whole kratom extracts confirmed that the extracts inhibited drug-metabolizing enzymes more strongly than the same concentration of isolated mitragynine alone, indicating that other alkaloids in the extract contribute additive inhibitory effects.14Scientific Reports. Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions If you are taking any prescription medication and using kratom extract, the interaction risk is real and unpredictable.
Cardiovascular Risks
Several of kratom’s major alkaloids suppress a specific potassium channel current in heart cells called IKr, which is critical for maintaining normal heart rhythm. In lab-grown human heart cells, mitragynine and three other kratom alkaloids suppressed this current by 67% to 84% and prolonged the electrical recovery phase of the heartbeat. Mitragynine also triggered abnormal rhythms (arrhythmia) in these cells.15PLOS ONE. Evaluation of the Cardiotoxicity of Mitragynine and Its Analogues Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes A separate study found that mitragynine inhibited the same channel current with high potency, reinforcing concerns about cardiac electrical stability.16Scientific Reports. Mitragynine, an euphoric compound inhibits hERG1a/1b channel current and upregulates the complexation of hERG1a-Hsp90 in HEK293-hERG1a/1b cells
These are cell-culture findings, and a lab dish is not the same as a living heart. But the mechanism they identify, prolonged QT interval, is a well-understood pathway to a dangerous type of arrhythmia.17Frontiers in Pharmacology. The Adverse Cardiovascular Effects and Cardiotoxicity of Kratom (Mitragyna speciosa Korth.): A Comprehensive Review The concern intensifies with extracts, where the alkaloid load per serving is much higher than with leaf powder. Case reports of cardiac events in kratom users exist, including cardiomyopathy and cardiac arrest, though these typically involved other risk factors or co-ingested substances.18PubMed Central. Unusual Presentation of Kratom Overdose With Rhabdomyolysis, Transient Hearing Loss, and Heart Failure
Liver Injury and Overdose
Kratom-related liver injury is uncommon but well-documented. An analysis from the U.S. Drug Induced Liver Injury Network identified eleven cases attributed to kratom, with a recent uptick. All patients developed jaundice with a typical onset about two weeks after starting use, and all eventually recovered.19PubMed Central. Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature At least one case involved severe liver failure with extremely elevated bilirubin levels requiring plasma exchange, with kratom identified as the cause after other possibilities were ruled out.20PubMed. Severe jaundice with life-threatening liver failure after Kratom use: Reversed by plasma exchange There is no specific antidote for kratom toxicity; treatment is supportive.
Overdose presentations are variable and hard for clinicians to pin down. A case series of ten kratom poisoning patients found that the dominant symptoms were neurological, primarily decreased consciousness. Vital signs were inconsistent across patients: some had high blood pressure and rapid heart rate, others had slow heart rate or cardiac arrest, and pupil responses varied. Naloxone, the standard opioid overdose reversal drug, helped some patients but not others. All ten survived, with symptoms resolving within two days.21PubMed. Mitragyna speciosa (Kratom) poisoning: Findings from ten cases Clinicians have also flagged rebound low-oxygen episodes occurring within 24 hours of overdose, and there is currently no standard urine or blood test that detects kratom.22PubMed Central. The Great Imitator: A Case of Accidental Kratom Overdose
Dependence and Withdrawal
Regular kratom use can produce physical dependence and withdrawal symptoms. A study assessing kratom use disorder found that most users in its sample experienced mild to moderate withdrawal and addiction symptoms. An important detail: withdrawal severity correlated more strongly with how often someone dosed rather than how much they took per dose.23PubMed Central. Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: Insights from dosing amount versus frequency Roughly 96% of participants in that study used whole-leaf products, with only about 4% using extracts regularly. This means the dependence data available largely reflects leaf use, and the dependence profile of concentrated extracts, with their higher alkaloid doses per serving, remains less well characterized but likely more intense.
Pregnancy and Neonatal Withdrawal
Kratom exposure during pregnancy has been linked to neonatal withdrawal. A systematic review of the available literature found six documented cases of prenatal kratom exposure, and in every case, both the mother and the newborn experienced withdrawal symptoms requiring treatment.24PubMed Central. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review At least one case report described a full-term newborn born to a chronic kratom user who required opioid medication to manage neonatal drug withdrawal.25PubMed Central. Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to ‘kratom’ The evidence base is small, but the direction is consistent and concerning.
Poison Center Data and the Scale of the Problem
The number of kratom-related calls to U.S. poison centers has surged. Between 2015 and 2025, poison centers documented over 14,400 kratom exposures, with the 3,434 reported in 2025 alone representing roughly a 1,200% increase over the 258 reported in 2015. Rates climbed steadily through 2019, plateaued during 2020 to 2024, and then spiked sharply in 2025. About 38% of all kratom exposure reports over the study period involved multiple substances.26Morbidity and Mortality Weekly Report. Increases in Kratom-Related Reports to Poison Centers — National Poison Data System, United States, 2015–2025 Earlier data covering 2011 to 2017 showed that most exposures were intentional, occurred in adult males, and roughly a third resulted in hospital admission.27PubMed. Kratom exposures reported to United States poison control centers: 2011-2017
The 2025 spike aligns with the rapid proliferation of high-potency extract and semi-synthetic products in the marketplace. It is difficult to separate the contribution of extracts from leaf products in poison center data, but the timing is suggestive.
Why Standard Drug Tests Miss Kratom
Kratom does not show up on standard drug screening panels, and even specialized testing for mitragynine has problems. A routine high-resolution mass spectrometry method used in clinical labs could not distinguish mitragynine from two of its closely related alkaloids, speciogynine and speciociliatine. All three were present in every positive patient sample tested, but at variable proportions.28PubMed Central. Drug testing for mitragynine and kratom: Analytical challenges and medico-legal considerations Without a method specifically designed to separate these compounds, labs can report falsely inflated mitragynine concentrations, which creates problems for forensic interpretation and for establishing what constitutes a toxic blood level.29Journal of Analytical Toxicology. The Trouble With Kratom: Analytical and Interpretative Issues Involving Mitragynine
For practical purposes, this means kratom use is invisible to most workplace drug tests and emergency-room toxicology screens. A person in the ER with an unexplained overdose presentation will not automatically be tested for kratom alkaloids unless a clinician specifically suspects it and requests specialized testing that their lab may or may not be equipped to perform.
Research Into Therapeutic Potential
Despite the risks, kratom remains an active area of pharmacological research precisely because its alkaloids interact with opioid receptors in unusual ways. In a small randomized, placebo-controlled trial, participants who drank kratom tea showed a significant increase in pain tolerance at one hour, roughly doubling the time they could endure a pain stimulus, compared to no change in the placebo group.30PubMed Central. Kratom and Pain Tolerance: A Randomized, Placebo-Controlled, Double-Blind Study In mice, freeze-dried kratom tea produced pain relief that depended on the mu-opioid receptor, did not cause the coordination problems or reward-seeking behavior associated with conventional opioids, and only briefly reduced breathing. Repeated dosing did not produce physical dependence in the mice and actually reduced withdrawal symptoms in mice that were already dependent on morphine.31PubMed. Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence
These findings are early-stage and do not justify treating kratom extract as a proven therapy. The gap between a controlled laboratory dose of characterized kratom tea and a gas-station extract shot of unknown composition is enormous. But they help explain why some people gravitate toward kratom for pain or opioid withdrawal management, and they suggest that some of the plant’s alkaloids, properly studied and dosed, could eventually inform new medications. The challenge is that the unregulated market has gotten far ahead of the science, putting consumers in the position of experimenting with concentrated products whose contents and risks are genuinely uncertain.
The Contaminant Angle
Beyond the alkaloids themselves, kratom products can contain heavy metals and other elemental impurities. An assessment of published product analyses found that non-extract kratom products generally contained higher concentrations of elemental impurities than extract products or ready-to-drink preparations.32PubMed. Elemental impurities (heavy metals) in kratom products: an assessment of published individual product analyses This is one area where extracts may actually have an advantage: the concentration process can leave behind some of the plant-bound metals. Still, the absence of mandatory third-party testing means no category of kratom product comes with consistent assurance of purity.